ArcticZymes Technologies ASA (LTS:0DRV) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DRV ArcticZymes Technologies ASA LTS:0DRV
76 GF Score
Price kr18.50
GF Value kr23.96
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ArcticZymes Technologies ASA FFO per Share?

FFO per Share only applies to REITs.

LTS:0DRV
76GF Score
ArcticZymes Technologies ASA LTS:0DRV
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ArcticZymes Technologies ASA (LTS:0DRV) Overvalued in 2026?

Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued. The current stock price of kr18.50 is trading 22.8% below its estimated GF Value™ of kr23.96. GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.

Key valuation signals for LTS:0DRV:

  • FFO per Share:
  • GF Value™: kr23.96 vs. price of kr18.50 (22.8% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the LTS:0DRV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ArcticZymes Technologies ASA Business Description

Other Exchanges BIOTECO:SwedenAZT:Norway
Address Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
76GF Score

Get the complete analysis for LTS:0DRV

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.50
Price
kr23.96
GF Value